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Abstract
We are in the midst of a pandemic due to SARS-CoV-2. Pregnancy was identified among the 
risk factors for worse clinical outcomes in multiple studies. The optimal therapy in this group of 
patients remains to be defined. Here we present the case of a 39 years old Caucasian pregnant 
female at 31 weeks of gestation who was treated successfully with hydroxychloroquine, azithro-
mycin, remdesivir, prone therapy, and cesarean delivery of a healthy baby while on mechanical 
ventilation. The SARS-CoV-2 remained positive until the 39th day of hospitalization. We dis-
cussed the pathophysiology of the increase risk of infections during pregnancy and particularly 
the high risk of microthombosis and coagulopathy due to COVID-19. Ultimately the contribution 
of the medications used to the favorable outcomes remained unknown being more likely that 
the delivery helped resolve the infection. 
Introduction
The world as we know it has changed with the SARS-CoV-2 pandemic. The virus known 
to cause COVID-19 and has been particularly virulent, leading to a global health crisis. 
COVID-19 primarily presents with respiratory compromise, often leading to acute re-
spiratory distress syndrome (ARDS) and multi-organ failure. Multiple studies have 
postulated the role of thromboembolic events as a vital trigger for COVID-19 induced 
coagulopathy. [1] The pathogenesis of the disease remains to be determined, however 
observational studies suggest the integral role of endothelial activation and microthrom-
bosis with disseminated organ damage as the cause for increased morbidity and mortal-
ity. [2] Some patient populations are noted to have a higher predisposition to COVID-19 
such as those with history of asthma, chronic obstructive pulmonary disease, cardiovas-
cular disease and pregnancy. Of note, pregnancy itself is described as a pro-coagulant 
state. The progression and severity of COVID-19 is not yet well defined or studied in the 
pregnant population.
In this article, we describe a case of a pregnant patient who developed ARDS with ac-
celerated respiratory failure requiring intubation and further intensive care unit (ICU) 
management. We hypothesize her disease process was accelerated by her pregnancy and 
outline her case and management here. Additionally, we performed a literature review of 
available treatments and compare those with the management strategies utilized in this 
patient
Case Description
The patient was a 39-year-old Caucasian female with a past medical history of bicuspid 
aortic valve and type 1 myotonic dystrophy. She presented to the Emergency Department 
(ED) at 31 weeks gestation with a two-day history of cough, headache and fever. She had 
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known exposure to a COVID-19 positive individual prior to presentation. The patient was discharged home due to her 
mild symptoms and clinical stability. She was advised to return if symptoms worsened. 
Four days later, the patient presented with worsening shortness of breath and her vitals on presentation were notable 
for a fever of 101.6 F with an oxygen saturation of 89% on room air. Chest x-ray and computed tomography angiography 
of the chest showed bilateral patchy infiltrates (Figure 1 and Figure 2). White blood cell count was consistent with 
lymphopenia and a procalcitonin was elevated at 0.33. The patient was initially admitted to the medical floor on 3L of 
oxygen via nasal cannula. However, she decompensated quickly with an arterial blood gas remarkable for a PaO2/FiO2 
ratio of 142, consistent with moderately severe ARDS. As a result, she was transferred ICU, intubated and mechanically 
ventilated.  The patient was started on ceftriaxone, azithromycin and hydroxychloroquine. COVID-19 infection was 
confirmed via nasopharyngeal swab four days after admission. 
The patient’s respiratory status continued to decline and proning was indicated for improved alveolar recruitment. 
There was hesitation to prone due to the need for continuous fetal monitoring however the anticipated benefit of pron-
ing was determined to outweigh the need for supine positioning to accommodate fetal monitoring. Despite proning, the 
patient developed ventilator desynchrony which required heavy sedation and cistacuronium for seven days. Ultimately 
a 10-day treatment course with remdesivir was initiated as the patient failed to improve with the aforementioned man-
agement. 
On the ninth hospital day, the patient underwent cesarean section with safe delivery of a healthy baby boy which led to 
significant improvement in her ability to oxygenate. The amniotic fluid and placenta tissue culture were negative for 
COVID-19 infection.
The patient continued to have intermittent febrile episodes and elevation in procalcitonin which led to concern for 
ventilator associated pneumonia with sputum cultures growing methicillin-susceptible Staphylococcus aureus. She 
completed a seven-day course of cefepime and vancomycin with repeat chest x-ray indicating improvement of bilateral 
pulmonary infiltrates.  
As she was making significant improvement in her respiratory status, the patient was extubated, however she required 
subsequent re-intubation within a few hours due to increased work of breathing. The patient underwent tracheosto-
my placement due to difficulty in weaning off mechanical ventilation. This was attributed to the combination of the 
patient’s history of myotonic dystrophy, prolonged immobility and presumed critical care neuromuscular weakness. 
She made significant improvement while working with physical and occupational therapy in regaining her strength 
and was slowly weaned off mechanical ventilation. Repeat imaging showed continued improvement of her multifocal 
pneumonia. Shortly thereafter, she was transitioned to a tracheostomy collar and decannulated prior to discharge. Of 
note, she continued to test positive for COVID-19 from the SARS-CoV-2 NP PCR until the 39th day of her hospital stay. 
The patient was able to recover from her illness after 41 days in the ICU setting and was discharged home in stable 
condition.
Figure 1. Patchy areas of opacity seen within both lungs, left greater than right. Infection, 
including both viral and bacterial pneumonia is favored over edema.
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Figure 2. Heterogenous areas of patchy ground glass opacity and septal thickening bilateral 
most compatible with an infectious etiology.
Discussion
This case highlights the rapid progression of COVID-19 infection to ARDS in vulnerable populations. Pregnant women 
are known to be at a higher risk of severe illness and higher mortality from viral infections noticeably during pandemics 
such as Ebola and influenza. [3-5] Infected women also have an increased incidence of cesarean delivery and preterm 
birth. There have been no reported cases of vertical transmission of COVID-19. [6] Being a relatively new disease pro-
cess, limited data is available on COVID-19 in pregnant patients. A comprehensive systematic review published recent-
ly reviewed perinatal outcomes in pregnant patients with COVID-19. A total of 114 pregnant women were included 
in the review and the most commonly reported symptoms were fever (87.5%) and cough (53.8%), followed closely by 
fatigue (22.5%), myalgia (16.3%) and dyspnea (11.3%). The majority of studied women had a cesarean section for var-
ious reasons; however, the fetal outcomes were fairly good. Preterm birth (21.3%) and fetal distress (10.7%) were the 
most prevalent outcomes. There were no reports of neonatal infection noted, however the majority of patients were 
in the third trimester of pregnancy and further studies are needed to evaluate neonatal transmission of COVID-19. [7] 
COVID-19 was not detected in the neonate, placenta or amniotic fluid in our case. 
Pregnancy is a unique immunologic state in which the body has to adapt to the fetus – especially acting as a foreign 
body – with a resulting increased susceptibility to a variety of infections. The progressive uterine distention during 
pregnancy is the major cause for chest wall and lung volume changes. Pregnancy- related reduction in functional 
residual capacity combined with increase in oxygen consumption lowers the oxygen reserve of the mother. [8] This 
could explain the significant improvement in oxygenation in our case after undergoing cesarean delivery. There is also 
evidence showing improved outcomes using higher positive end-expiratory pressure and manual prone positioning, 
which were utilized in our patient. [9]
The immune system plays an important role in regulation of normal and pathologic states of pregnancy. Some pro-in-
flammatory cytokines, namely TNF-a, IL-1b and IL-6, IL-10 and regulatory T cells (T reg), have recently been found to 
have immunosuppressive properties in the setting of pregnancy, appearing to play a critical role in both immune stimu-
latory and counter regulatory functions. It has been shown in COVID-19 infections that IL-6,IL-10, and TNF-a increase 
the expression of programmed cell death marker-1 (PD-1) causing cell death and severe disease, which eventually can 
be used as prognostic factors in stratification of disease severity and possibly change management. [10] In our case, the 
use of two immunomodulator agents (hydroxychloroquine and azithromycin) may have exacerbated the immunosup-
pressive state and promoted the persistence of viral carriage for over a month which could have been detrimental. It is 
unknown if remdesivir had any impact on this patient’s clinical outcome. The delivery of the baby appears to have been 
the main contributing factor to improvement in oxygenation. 
Severe COVID-19 has been associated with a coagulopathic state with elevated D-Dimer and fibrinogen levels. [11] 
Pregnancy-related hypercoagulability is an adaptive mechanism to prevent post-partum hemorrhage. Fibrinogen and 
thrombin levels are noted to increase up to three times in pregnancy, while protein S, an anticoagulant factor, decreas-
es. Prolonged bed rest during pregnancy adds to the venous stasis and hypercoagulable state in pregnancy. [12] The 
hypercoagulable state of pregnancy plus the pro-thrombotic state of COVID-19 due to endothelial damage may explain 
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some of the worse outcomes during pregnancy.
Specific treatment protocols for COVID-19 in pregnancy with the administration of hydroxychloroquine, azithromycin 
have shown that there is no significant increased risk for malformations, intrauterine death, preterm delivery or low 
birth weight. There is no substantial evidence regarding remdesivir in pregnancy, however in this particular case, these 
treatments were administered in hope of changing the patient’s outcome and possibly shorten disease. It is difficult to 
determine whether this disease responded to these medications as our patient continued to test positive for over four 
weeks while in the ICU or was this a natural course of the disease itself.
In conclusion, our patient’s clinical course was likely prolonged due to complications from her type A blood, type 1 
muscular dystrophy, worsening immunosuppression due to immunomodulatory agents, and pregnancy. Conversely, fa-
vorable factors included supportive critical care, timely cesarean delivery which improved her respiratory function and 
thromboprophylaxis. It is still unclear if any of the medical treatments used had any benefit as further larger studies are 
needed to establish this definitively. It is also unclear if any of the medical treatments had any effect on viral shedding 
as the patient continued to test positive for four weeks following initial testing. Of the positive contributing factors, it 
was felt that supportive care had the most significant impact on the patient’s eventual positive outcome. 
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